ClinicalTrials.gg
RecruitingNCT07158047Updated Mar 4, 2026

Repeated Far Infrared Sauna Bathing in Adults With Obesity

An interventional study of Heat therapy in Obesity (Disorder), sponsored by University of Oregon. Recruiting at 1 site in United States. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by University of Oregon · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 3 years 5 months after the study started (first participant enrolled Mar 2022, registered Aug 2025).
  • Started Mar 2022; still recruiting 4 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Study summary

This is a clinical trial to determine if 30 sessions of far infrared sauna bathing can improve cardiovascular and metabolic function in adults with obesity.

Read the detailed description

Obesity can increase the risk for cardiovascular and metabolic diseases. Lifestyle interventions are needed to reduce this risk. Far infrared saunas are one form of heat therapy that may help reduce these risks, however, there is limited research within a population with obesity. It is hypothesized that repeated far infrared sauna bathing will improve cardiovascular and metabolic function in adults with obesity.

02

Conditions studied

  • Obesity (Disorder)

Keywords

  • heat therapy
  • insulin resistance
  • arterial stiffness
  • blood pressure
  • obesity
  • sauna
  • vascular health
  • cardiovascular
  • metabolic function
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 20 is below the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Oregon is the lead sponsor of 75 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 30-45 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Diagnosed diabetes
  • Greater than stage 2 hypertension
  • Coagulopathies
  • Allergies to lidocaine
  • Medications affecting blood pressure
  • Blood clotting, and blood sugars
  • Smoker
  • Pregnant
  • Desiring to become pregnant in the near future
  • Breastfeeding
  • less than 30
  • BMI greater than 45 kg/m2
  • Exercising > 120 min/week
  • Taking medications (other than hormone )
  • Not willing to stop taking medications (other than hormone contraceptives) for 24 hours before testing days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Heat therapy

    Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require participants to sit in a far infrared sauna for up to 45 min for 3 to 4 times per week.

    Other: Heat therapy

  • No intervention
    Time control group

    No participation in sauna bathing. Maintain lifestyle habits for approximately 10 weeks.

Interventions

  • OtherHeat therapy

    30 sessions of far infrared sauna bathing (45-60C) for up to 45 min

    Also known as: sauna bathing

06

What researchers measure

Primary outcomes

  1. Blood pressure change

    Change in systolic and diastolic blood pressures after 30 sessions of Intervention

    Time frame: 10 weeks

  2. Blood glucose

    Change in plasma glucose levels after Intervention

    Time frame: 10 weeks

Secondary outcomes

  1. Arterial stiffness reduction

    Change in Carotid-femoral Pulse Wave Velocity (m/s) after Intervention

    Time frame: 10 weeks

  2. Serum insulin

    Change in serum insulin levels after Intervention

    Time frame: 10 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Masuda A, Koga Y, Hattanmaru M, Minagoe S, Tei C. The effects of repeated thermal therapy for patients with chronic pain. Psychother Psychosom. 2005;74(5):288-94. doi: 10.1159/000086319. PubMed 16088266 ↗
  • Kihara T, Biro S, Imamura M, Yoshifuku S, Takasaki K, Ikeda Y, Otuji Y, Minagoe S, Toyama Y, Tei C. Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure. J Am Coll Cardiol. 2002 Mar 6;39(5):754-9. doi: 10.1016/s0735-1097(01)01824-1. PubMed 11869837 ↗
  • Kihara T, Biro S, Ikeda Y, Fukudome T, Shinsato T, Masuda A, Miyata M, Hamasaki S, Otsuji Y, Minagoe S, Akiba S, Tei C. Effects of repeated sauna treatment on ventricular arrhythmias in patients with chronic heart failure. Circ J. 2004 Dec;68(12):1146-51. doi: 10.1253/circj.68.1146. PubMed 15564698 ↗
  • Fuchs CJ, Betz MW, Petrick HL, Weber J, Senden JM, Hendriks FK, Bels JLM, van Loon LJC, Snijders T. Repeated passive heat treatment increases muscle tissue capillarization, but does not affect postprandial muscle protein synthesis rates in healthy older adults. J Physiol. 2025 Jan;603(1):167-186. doi: 10.1113/JP286986. Epub 2024 Oct 7. PubMed 39373667 ↗
  • Ely BR, Francisco MA, Halliwill JR, Bryan SD, Comrada LN, Larson EA, Brunt VE, Minson CT. Heat therapy reduces sympathetic activity and improves cardiovascular risk profile in women who are obese with polycystic ovary syndrome. Am J Physiol Regul Integr Comp Physiol. 2019 Nov 1;317(5):R630-R640. doi: 10.1152/ajpregu.00078.2019. Epub 2019 Sep 4. PubMed 31483156 ↗
  • Ely BR, Clayton ZS, McCurdy CE, Pfeiffer J, Needham KW, Comrada LN, Minson CT. Heat therapy improves glucose tolerance and adipose tissue insulin signaling in polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2019 Jul 1;317(1):E172-E182. doi: 10.1152/ajpendo.00549.2018. Epub 2019 May 28. PubMed 31136202 ↗
  • Brunt VE, Jeckell AT, Ely BR, Howard MJ, Thijssen DH, Minson CT. Acute hot water immersion is protective against impaired vascular function following forearm ischemia-reperfusion in young healthy humans. Am J Physiol Regul Integr Comp Physiol. 2016 Dec 1;311(6):R1060-R1067. doi: 10.1152/ajpregu.00301.2016. Epub 2016 Oct 5. PubMed 27707723 ↗
  • Brunt VE, Eymann TM, Francisco MA, Howard MJ, Minson CT. Passive heat therapy improves cutaneous microvascular function in sedentary humans via improved nitric oxide-dependent dilation. J Appl Physiol (1985). 2016 Sep 1;121(3):716-23. doi: 10.1152/japplphysiol.00424.2016. Epub 2016 Jul 14. PubMed 27418688 ↗
  • Behzadi P, Ravanelli N, Gravel H, Barry H, Debray A, Chaseling GK, Jacquemet V, Neagoe PE, Nigam A, Carpentier AC, Sirois MG, Gagnon D. Acute effect of passive heat exposure on markers of cardiometabolic function in adults with type 2 diabetes mellitus. J Appl Physiol (1985). 2022 May 1;132(5):1154-1166. doi: 10.1152/japplphysiol.00800.2021. Epub 2022 Mar 24. PubMed 35323077 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jun 2026, 51 months after the start.

Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 51 months is above that.

Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 5, 2025
StartActual
Mar 7, 2022
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jul 31, 2026
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07158047
Lead sponsor
University of Oregon
Responsible party
Christopher T Minson, PhD (Professor, University of Oregon) — Principal investigator
First posted
Sep 5, 2025
Start date
Mar 7, 2022
Primary completion
Jun 30, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Mar 4, 2026

Study contacts

Christopher T Minson, PhD
Contact
minson@uoregon.edu
541-346-7583
John R Halliwill, PhD
Contact
halliwil@uoregon.edu
541-346-7591
Christopher T Minson, PhD
principal investigator · University of Oregon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion